|3.08||+0.1000||+3.36%||Vol 118.77K||1Y Perf -57.12%|
|Oct 4th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||7.00||Analyst Rating||Hold 3.00|
|Potential %||127.27||Finscreener Ranking||★ 41.83|
|Insiders Trans % 3/6/12 mo.||-/-100/-75||Value Ranking||★+ 41.99|
|Insiders Value % 3/6/12 mo.||-/-100/-96||Growth Ranking||★ 37.31|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-97||Income Ranking||— -|
|Price Range Ratio 52W %||30.44||Earnings Rating||—|
|Market Cap||242.03M||Earnings Date||20th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||20th Nov 2023|
|Estimated EPS Next Report||0.06|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||167.60K|
|Avg. Monthly Volume||201.79K|
|Avg. Quarterly Volume||312.37K|
Bioventus Inc. (NASDAQ: BVS) stock closed at 2.98 per share at the end of the most recent trading day (a -6.29% change compared to the prior day closing price) with a volume of 127.77K shares and market capitalization of 242.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 680 people. Bioventus Inc. CEO is Kenneth M. Reali.
The one-year performance of Bioventus Inc. stock is -57.12%, while year-to-date (YTD) performance is 14.18%. BVS stock has a five-year performance of %. Its 52-week range is between 0.7999 and 8.29, which gives BVS stock a 52-week price range ratio of 30.44%
Bioventus Inc. currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 0.67, a price-to-sale (PS) ratio of 0.43, a price to cashflow ratio of 28.30, a PEG ratio of -, a ROA of -12.39%, a ROC of -21.48% and a ROE of -51.28%. The company’s profit margin is -43.63%, its EBITDA margin is -29.30%, and its revenue ttm is $386.28 Million , which makes it $6.24 revenue per share.
Of the last four earnings reports from Bioventus Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.06 for the next earnings report. Bioventus Inc.’s next earnings report date is 20th Nov 2023.
The consensus rating of Wall Street analysts for Bioventus Inc. is Hold (3), with a target price of $7, which is +127.27% compared to the current price. The earnings rating for Bioventus Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bioventus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bioventus Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 62.76, ATR14 : 0.22, CCI20 : -43.83, Chaikin Money Flow : -0.09, MACD : -0.13, Money Flow Index : 38.04, ROC : -2.30, RSI : 42.02, STOCH (14,3) : 30.00, STOCH RSI : 0.32, UO : 50.57, Williams %R : -70.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bioventus Inc. in the last 12-months were: Anthony DÂ¿Adamio (Option Excercise at a value of $0), Anthony DÂ¿Adamio (Sold 3 409 shares of value $4 737 ), Bartholdson John A. (Buy at a value of $1 338 165), Bartholdson John A. (Option Exercise at a value of $0), Beyer Pat (Option Exercise at a value of $0), D'Adamio Anthony (Sold 0 shares of value $0 ), D'Adamio Anthony (Sold 3 409 shares of value $4 739 ), Guido J. Neels (Option Excercise at a value of $0), Hawkins William (Buy at a value of $235 400), Hawkins William (Option Excercise at a value of $0), HAWKINS WILLIAM A (Option Exercise at a value of $0), Katrina Church (Option Excercise at a value of $0), Katrina Church (Sold 1 449 shares of value $1 975 ), Katrina J. Church (Option Excercise at a value of $0), Katrina J. Church (Sold 1 843 shares of value $3 092 ), Kenneth M. Reali (Option Excercise at a value of $0), Kenneth M. Reali (Sold 9 811 shares of value $13 625 ), Ladone Mary (Option Excercise at a value of $0), Ladone Mary Kay (Option Exercise at a value of $0), Mark Leonard Singleton (Sold 0 shares of value $0 ), Mark Leonard Singleton (Sold 6 044 shares of value $7 676 ), McMurry-Heath Michelle (Option Exercise at a value of $0), Michelle Mcmurry-Heath (Option Excercise at a value of $0), NEELS GUIDO J (Option Exercise at a value of $0), Nohra Guy (Option Excercise at a value of $0), NOHRA GUY P (Option Exercise at a value of $0), Pat Beyer (Option Excercise at a value of $0), Reali Kenneth (Sold 0 shares of value $0 ), Reali Kenneth (Sold 9 811 shares of value $13 637 ), Stalnecker Susan (Option Excercise at a value of $0), STALNECKER SUSAN M (Option Exercise at a value of $0), Sutter Martin (Option Excercise at a value of $0), SUTTER MARTIN P (Option Exercise at a value of $0), William A. Hawkins (Option Excercise at a value of $0)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.